Full-Time

Senior Data Engineer

Confirmed live in the last 24 hours

Biorender

Biorender

201-500 employees

Online platform for creating scientific illustrations

No salary listed

Senior, Expert

Remote in USA + 1 more

More locations: Remote in Canada

Remote work is available for candidates based in the US and Canada.

Category
Data Engineering
Data & Analytics
Required Skills
Python
Airflow
Apache Spark
SQL
Snowflake
Requirements
  • 7+ years of data engineering experience of relevant industry experience
  • Expertise working with Data Warehousing platforms (AWS RedShift or Snowflake preferred) and data lake / lakehouse architectures
  • Experience with Data Streaming platforms (AWS Kinesis / Firehose preferred)
  • Demonstrated ability to (creatively) solve complex architectural problems, think about tradeoffs and systems design
  • Effective communication skills and ability to translate deeply technical designs into business appropriate representations as well as analyze business needs and requirements ensuring implementation of data services directly correlates to the strategy and growth of the business
  • Expertise with SQL and programming languages commonly used in data platforms (Python, Spark, etc)
  • Experience with data pipeline orchestration (e.g., Airflow) and data pipeline integrations (e.g. Airbyte, Stitch)
Desired Qualifications
  • Detail-oriented, process-oriented, data-focused, and good at picking up on data inconsistencies
  • Growth mindset, excited to learn new libraries / technologies but extremely practical and deliberate about adopting them for production. Extremely thoughtful about tradeoffs between different tools and whether they are solving the right problems for the team and for our users
  • Strong work ethic with a focus on delivering results
  • Inquisitive, thorough, and pragmatic
  • Excellent communication skills with the ability to explain complex solutions/problems clearly and succinctly to the team and internal stakeholders
  • Enjoys working cross-functionally and helping teammates work more effectively
  • Proficiency in dbt, sdf, or an equivalent SQL development framework
  • Hands-on experience with data mesh architecture
  • Experience with Data as a Product (DaaP) principles, emphasizing data discoverability, quality, security, and self-service accessibility

BioRender provides an online platform for creating and sharing scientific illustrations tailored for the life sciences sector. Users can access thousands of pre-drawn icons and templates across more than 30 life sciences fields, allowing scientists, researchers, and educators to produce professional and visually appealing figures efficiently. The platform is designed to simplify the illustration process, making it easier for clients such as academic researchers, pharmaceutical companies, and educational institutions to create figures for research papers, presentations, and educational materials. BioRender operates on a subscription-based model, offering various plans that cater to different user needs, including enterprise solutions for larger organizations. The company's goal is to streamline the creation of scientific figures, saving users time and effort while enhancing the quality of scientific communication.

Company Size

201-500

Company Stage

Series A

Total Funding

$17.2M

Headquarters

Toronto, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for digital communication boosts need for scientific visualization tools.
  • Growing interest in graphical abstracts enhances research visibility and accessibility.
  • Open-access publishing trend increases demand for high-quality, appealing figures.

What critics are saying

  • AI-driven design tools may reduce demand for BioRender's platform.
  • Increased competition from cheaper visualization platforms could erode market share.
  • Potential IP disputes over pre-drawn icons could lead to legal challenges.

What makes Biorender unique

  • BioRender offers a vast library of customizable icons and templates for scientists.
  • The platform provides a user-friendly interface for creating professional scientific figures.
  • BioRender serves diverse clients, including academia, biotech, and pharmaceutical companies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

3%

2 year growth

6%
PR Newswire
Nov 12th, 2024
Researchers Uncover New Role Of Mutant Proteins In Some Of The Deadliest Cancers

Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they found, helps to kick off a series of events involving the transport of specific nuclear proteins that lead to uncontrolled tumor growth, according to a study published Nov. 11, 2024, in Nature Cancer

PR Newswire
Apr 13th, 2023
Peel Therapeutics Reports Excessive Netosis Induction In Long Covid

Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis

Labiotech
Aug 24th, 2022
Study Findings Could Lead To New Anti-Cancer Drugs

Cancer cells surround themselves with a cloud of adenosine, thereby inhibiting the immune system (left). Ceritinib stops the formation of adenosine. ATP accumulates and activates immune cells (right). Figure: Laura Schäkel/University of Bonn – created with BioRender.com. German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system

WFMZ
Jun 15th, 2020
BioRender launched Graphical Abstract Contest on Jun 15th 20'.

Today BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.